192 related articles for article (PubMed ID: 27796912)
1. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
[TBL] [Abstract][Full Text] [Related]
2. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
4. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
Miravitlles M; Gáldiz JB; Huerta A; Villacampa A; Carcedo D; Garcia-Rio F
Int J Chron Obstruct Pulmon Dis; 2016; 11():123-32. PubMed ID: 26848262
[TBL] [Abstract][Full Text] [Related]
6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Driessen MT; Whalen J; Seewoodharry Buguth B; Vallejo-Aparicio LA; Naya IP; Asukai Y; Alcázar-Navarrete B; Miravitlles M; García-Río F; Risebrough NA
Respir Res; 2018 Nov; 19(1):224. PubMed ID: 30458866
[TBL] [Abstract][Full Text] [Related]
8. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.
Feldman G; Maltais F; Khindri S; Vahdati-Bolouri M; Church A; Fahy WA; Trivedi R
Int J Chron Obstruct Pulmon Dis; 2016; 11():719-30. PubMed ID: 27103795
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
Covelli H; Pek B; Schenkenberger I; Scott-Wilson C; Emmett A; Crim C
Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y; Duan S; Zhang L; Peng F
Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Huisman EL; Cockle SM; Ismaila AS; Karabis A; Punekar YS
Int J Chron Obstruct Pulmon Dis; 2015; 10():1863-81. PubMed ID: 26392761
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Siler TM; Kerwin E; Singletary K; Brooks J; Church A
COPD; 2016; 13(1):1-10. PubMed ID: 26451734
[TBL] [Abstract][Full Text] [Related]
13. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Church A; Beerahee M; Brooks J; Mehta R; Shah P
BMC Pulm Med; 2014 Jan; 14():2. PubMed ID: 24393134
[TBL] [Abstract][Full Text] [Related]
14. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
Zhai C; Wang F; Xu R; Sun X; Ma W; Wang L
Postgrad Med J; 2024 Apr; ():. PubMed ID: 38652265
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK.
Punekar YS; Roberts G; Ismaila A; O'Leary M
Cost Eff Resour Alloc; 2015; 13():22. PubMed ID: 26692823
[TBL] [Abstract][Full Text] [Related]
16. The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models.
Buikema AR; Brekke L; Anderson A; Koep E; Van Voorhis D; Sharpsten L; Hahn B; Ray R; Stanford RH
Multidiscip Respir Med; 2018; 13():38. PubMed ID: 30338068
[TBL] [Abstract][Full Text] [Related]
17. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial.
Kesten S; Celli B; Decramer M; Liu D; Tashkin D
Respir Res; 2011 Sep; 12(1):129. PubMed ID: 21955733
[TBL] [Abstract][Full Text] [Related]
18. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
[TBL] [Abstract][Full Text] [Related]
19. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
Westwood M; Bourbeau J; Jones PW; Cerulli A; Capkun-Niggli G; Worthy G
Respir Res; 2011 Apr; 12(1):40. PubMed ID: 21477298
[TBL] [Abstract][Full Text] [Related]
20. A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data.
Saville BR; Herring AH; Koch GG
Stat Med; 2010 Jan; 29(1):75-85. PubMed ID: 19830704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
